179 related articles for article (PubMed ID: 16686529)
1. 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Brussee J; Ijzerman AP
J Med Chem; 2006 May; 49(10):2861-7. PubMed ID: 16686529
[TBL] [Abstract][Full Text] [Related]
2. 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
Chang LC; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Westerhout J; Spangenberg T; Brussee J; Ijzerman AP
J Med Chem; 2007 Feb; 50(4):828-34. PubMed ID: 17300165
[TBL] [Abstract][Full Text] [Related]
3. 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; van den Hout G; Beukers MW; Brussee J; Ijzerman AP
J Med Chem; 2004 Dec; 47(26):6529-40. PubMed ID: 15588088
[TBL] [Abstract][Full Text] [Related]
4. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
[TBL] [Abstract][Full Text] [Related]
5. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Aug; 60(8):643-51. PubMed ID: 15961085
[TBL] [Abstract][Full Text] [Related]
7. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.
Giorgi I; Leonardi M; Pietra D; Biagi G; Borghini A; Massarelli I; Ciampi O; Bianucci AM
Bioorg Med Chem; 2009 Mar; 17(5):1817-30. PubMed ID: 19230680
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Romagnoli R; Preti D; Bovero A; Pineda de Las Infantas MJ; Moorman A; Varani K; Borea PA
J Med Chem; 2004 Oct; 47(22):5535-40. PubMed ID: 15481989
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Apr; 60(4):299-306. PubMed ID: 15848204
[TBL] [Abstract][Full Text] [Related]
12. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
[TBL] [Abstract][Full Text] [Related]
15. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.
van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; Ijzerman AP
J Med Chem; 1998 Oct; 41(21):3994-4000. PubMed ID: 9767637
[TBL] [Abstract][Full Text] [Related]
16. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
Chang LC; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Spanjersberg RF; Roerink SF; van den Hout G; Beukers MW; Brussee J; Ijzerman AP
J Med Chem; 2005 Mar; 48(6):2045-53. PubMed ID: 15771447
[TBL] [Abstract][Full Text] [Related]
17. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Jordan AM; Knight AR; Lerpiniere J; Misra A; Pratt RM; Roffey J; Stratton GC; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2924-9. PubMed ID: 18411049
[TBL] [Abstract][Full Text] [Related]
18. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.
Kiesman WF; Zhao J; Conlon PR; Dowling JE; Petter RC; Lutterodt F; Jin X; Smits G; Fure M; Jayaraj A; Kim J; Sullivan G; Linden J
J Med Chem; 2006 Nov; 49(24):7119-31. PubMed ID: 17125264
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors.
van den Nieuwendijk AM; Pietra D; Heitman L; Göblyös A; IJzerman AP
J Med Chem; 2004 Jan; 47(3):663-72. PubMed ID: 14736246
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
